119 related articles for article (PubMed ID: 28704096)
1. EPIDEMIOLOGY OF GASTROINTESTINAL NEUROENDOCRINE TUMORS IN A U.S. COMMERCIALLY INSURED POPULATION.
Broder MS; Cai B; Chang E; Neary MP
Endocr Pract; 2017 Oct; 23(10):1210-1216. PubMed ID: 28704096
[TBL] [Abstract][Full Text] [Related]
2. Incidence and prevalence of neuroendocrine tumors of the lung: analysis of a US commercial insurance claims database.
Broder MS; Cai B; Chang E; Neary MP
BMC Pulm Med; 2018 Aug; 18(1):135. PubMed ID: 30103725
[TBL] [Abstract][Full Text] [Related]
3. INCIDENCE AND PREVALENCE OF ACROMEGALY IN THE UNITED STATES: A CLAIMS-BASED ANALYSIS.
Broder MS; Chang E; Cherepanov D; Neary MP; Ludlam WH
Endocr Pract; 2016 Nov; 22(11):1327-1335. PubMed ID: 27540880
[TBL] [Abstract][Full Text] [Related]
4. Incidence and prevalence of acromegaly in a large US health plan database.
Burton T; Le Nestour E; Neary M; Ludlam WH
Pituitary; 2016 Jun; 19(3):262-7. PubMed ID: 26792654
[TBL] [Abstract][Full Text] [Related]
5. First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA.
Broder MS; Cai B; Chang E; Yan T; Benson AB
J Med Econ; 2018 Aug; 21(8):821-826. PubMed ID: 29741466
[TBL] [Abstract][Full Text] [Related]
6. Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States.
Lee MR; Harris C; Baeg KJ; Aronson A; Wisnivesky JP; Kim MK
Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2212-2217.e1. PubMed ID: 30580091
[TBL] [Abstract][Full Text] [Related]
7. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
Dasari A; Shen C; Halperin D; Zhao B; Zhou S; Xu Y; Shih T; Yao JC
JAMA Oncol; 2017 Oct; 3(10):1335-1342. PubMed ID: 28448665
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014.
Hunter TM; Boytsov NN; Zhang X; Schroeder K; Michaud K; Araujo AB
Rheumatol Int; 2017 Sep; 37(9):1551-1557. PubMed ID: 28455559
[TBL] [Abstract][Full Text] [Related]
9. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan.
Ito T; Sasano H; Tanaka M; Osamura RY; Sasaki I; Kimura W; Takano K; Obara T; Ishibashi M; Nakao K; Doi R; Shimatsu A; Nishida T; Komoto I; Hirata Y; Nakamura K; Igarashi H; Jensen RT; Wiedenmann B; Imamura M
J Gastroenterol; 2010 Feb; 45(2):234-43. PubMed ID: 20058030
[TBL] [Abstract][Full Text] [Related]
10. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Cushing's syndrome and Cushing's disease in commercially-insured patients <65 years old in the United States.
Broder MS; Neary MP; Chang E; Cherepanov D; Ludlam WH
Pituitary; 2015 Jun; 18(3):283-9. PubMed ID: 24803324
[TBL] [Abstract][Full Text] [Related]
12. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis.
Ito T; Igarashi H; Nakamura K; Sasano H; Okusaka T; Takano K; Komoto I; Tanaka M; Imamura M; Jensen RT; Takayanagi R; Shimatsu A
J Gastroenterol; 2015 Jan; 50(1):58-64. PubMed ID: 24499825
[TBL] [Abstract][Full Text] [Related]
13. Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study.
Cai W; Tan Y; Ge W; Ding K; Hu H
Cancer Med; 2018 Jun; 7(6):2699-2709. PubMed ID: 29733523
[TBL] [Abstract][Full Text] [Related]
14. Distribution of gastrointestinal neuroendocrine tumors in Europe: results from a retrospective cross-sectional study.
Loosen SH; Kostev K; Jann H; Tetzlaff F; Tacke F; Krieg S; Knoefel WT; Fluegen G; Luedde T; Krieg A; Roderburg C
J Cancer Res Clin Oncol; 2023 Apr; 149(4):1411-1416. PubMed ID: 35476234
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors.
Cai B; Broder MS; Chang E; Yan T; Metz DC
World J Gastroenterol; 2017 Oct; 23(40):7283-7291. PubMed ID: 29142475
[TBL] [Abstract][Full Text] [Related]
16. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
17. Incidence and prevalence of basal cell carcinoma (BCC) and locally advanced BCC (LABCC) in a large commercially insured population in the United States: A retrospective cohort study.
Goldenberg G; Karagiannis T; Palmer JB; Lotya J; O'Neill C; Kisa R; Herrera V; Siegel DM
J Am Acad Dermatol; 2016 Nov; 75(5):957-966.e2. PubMed ID: 27473450
[TBL] [Abstract][Full Text] [Related]
18. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971.
Ellis L; Shale MJ; Coleman MP
Am J Gastroenterol; 2010 Dec; 105(12):2563-9. PubMed ID: 20823835
[TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis prevalence in the United States commercially insured population.
Dilokthornsakul P; Valuck RJ; Nair KV; Corboy JR; Allen RR; Campbell JD
Neurology; 2016 Mar; 86(11):1014-21. PubMed ID: 26888980
[TBL] [Abstract][Full Text] [Related]
20. Incidence and risk factors of gastrointestinal neuroendocrine neoplasm metastasis in liver, lung, bone, and brain: A population-based study.
Zheng Z; Chen C; Jiang L; Zhou X; Dai X; Song Y; Li Y
Cancer Med; 2019 Dec; 8(17):7288-7298. PubMed ID: 31609098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
